Abhijeet Kapoor

Abhijeet Kapoor

Auto-generated profile, based on publicly available information

Abhijeet Kapoor

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AKAndrew C. Kruegel
Andrew C. Kruegel
MGMadalee M. Gassaway
Madalee M. Gassaway
AKAbhijeet Kapoor
Abhijeet Kapoor
AVAndras Varadi
Andras Varadi
SMSusruta Majumdar
Susruta Majumdar
DSDalibor Sames
Dalibor Sames

1 January 2018 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
THTaylor E. T. Hughes
Taylor E. T. Hughes
DLDavid T. Lodowski
David T. Lodowski
KHKevin W. Huynh
Kevin W. Huynh
AYAysenur Yazici
Aysenur Yazici
JRJohn Del Rosario
John Del Rosario
VMVera Y. Moiseenkova-Bell
Vera Y. Moiseenkova-Bell

25 October 2019 in eLife
Verified
Journal Article
Open access
THTaylor Et Hughes
Taylor Et Hughes
JRJohn Smith Del Rosario
John Smith Del Rosario
AKAbhijeet Kapoor
Abhijeet Kapoor
AYAysenur Torun Yazici
Aysenur Torun Yazici
YYYevgen Yudin
Yevgen Yudin
VMVera Y Moiseenkova-Bell
Vera Y Moiseenkova-Bell
Transient receptor potential vanilloid 5 (TRPV5) is a highly calcium selective ion channel that acts as the rate-limiting step of calcium reabsorption in the kidney. The lack of potent, specific modulators of TRPV5 has limited the ability to probe the contribution of TRPV5 in disease phenotypes such as hypercalcemia and nephrolithiasis. Here, we performed structure-based virtual screening (SBVS) at a previously identified TRPV5 inhibitor binding site coupled with electrophysiology screening and identified three novel inhibitors of TRPV5, one of which exhibits high affinity, and specificity for TRPV5 over other TRP channels, including its close homologue TRPV6. Cryo-electron microscopy of TRPV5 in the presence of the specific inhibitor and its parent compound revealed novel binding sites for this channel. Structural and functional analysis have allowed us to suggest a mechanism of action for the selective inhibition of TRPV5 and lay the groundwork for rational design of new classes of TRPV5 modulators.

19 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSandip Basak
Sandip Basak
YGYvonne Gicheru
Yvonne Gicheru
AKAbhijeet Kapoor
Abhijeet Kapoor
MMMegan L. Mayer
Megan L. Mayer
MFMarta Filizola
Marta Filizola
SCSudha Chakrapani
Sudha Chakrapani
Serotonin receptor (5-HT3AR) is the most common therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of irritable bowel syndrome. Setrons, a class of competitive antagonists, cause functional inhibition of 5-HT3AR in the gastrointestinal tract and brainstem, acting as effective anti-emetic agents. Despite their prevalent use, the molecular mechanisms underlying setron binding and inhibition of 5-HT3AR are not fully understood. Here, we present the structure of granisetron-bound full-length 5-HT3AR solved by single-particle cryo-electron microscopy to 2.92 Å resolution. The reconstruction reveals the orientation of granisetron in the orthosteric site with unambiguous density for interacting sidechains. Molecular dynamics simulations and electrophysiology confirm the granisetron binding orientation and the residues central for ligand recognition. Comparison of granisetron-bound 5-HT3AR with the apo and serotonin-bound structures, reveals key insights into the mechanism underlying 5-HT3AR inhibition.

16 October 2020 in eLife
Verified
Journal Article
Open access
SBSandip Basak
Sandip Basak
AKArvind Kumar
Arvind Kumar
SRSteven Ramsey
Steven Ramsey
EGEric Gibbs
Eric Gibbs
AKAbhijeet Kapoor
Abhijeet Kapoor
SCSudha Chakrapani
Sudha Chakrapani
Serotonin receptors (5-HT3AR) play a crucial role in regulating gut movement, and are the principal target of setrons, a class of high-affinity competitive antagonists, used in the management of nausea and vomiting associated with radiation and chemotherapies. Structural insights into setron-binding poses and their inhibitory mechanisms are just beginning to emerge. Here, we present high-resolution cryo-EM structures of full-length 5-HT3AR in complex with palonosetron, ondansetron, and alosetron. Molecular dynamic simulations of these structures embedded in a fully-hydrated lipid environment assessed the stability of ligand-binding poses and drug-target interactions over time. Together with simulation results of apo- and serotonin-bound 5-HT3AR, the study reveals a distinct interaction fingerprint between the various setrons and binding-pocket residues that may underlie their diverse affinities. In addition, varying degrees of conformational change in the setron-5-HT3AR structures, throughout the channel and particularly along the channel activation pathway, suggests a novel mechanism of competitive inhibition.

12 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAbhijeet Kapoor
Abhijeet Kapoor
GMGerard Martinez-Rosell
Gerard Martinez-Rosell
DPDavide Provasi
Davide Provasi
GFGianni de Fabritiis
Gianni de Fabritiis
MFMarta Filizola
Marta Filizola
While the therapeutic effect of opioids analgesics is mainly attributed to µ-opioid receptor (MOR) activation leading to G protein signaling, their side effects have mostly been linked to β-arrestin signaling. To shed light on the dynamic and kinetic elements underlying MOR functional selectivity, we carried out close to half millisecond high-throughput molecular dynamics simulations of MOR bound to a classical opioid drug (morphine) or a potent G protein-biased agonist (TRV-130). Statistical analyses of Markov state models built using this large simulation dataset combined with information theory enabled, for the first time: a) Identification of four distinct metastable regions along the activation pathway, b) Kinetic evidence of a different dynamic behavior of the receptor bound to a classical or G protein-biased opioid agonist, c) Identification of kinetically distinct conformational states to be used for the rational design of functionally selective ligands that may eventually be developed into improved drugs; d) Characterization of multiple activation/deactivation pathways of MOR, and e) Suggestion from calculated transition timescales that MOR conformational changes are not the rate-limiting step in receptor activation.